达格列净用于合并法布雷病的CKD患者
这项前瞻性多中心研究评估达格列净10 mg对合并白蛋白尿性CKD的法布雷病患者的12个月疗效。
要点
- 达格列净使法布雷病合并CKD患者UACR下降47.6%、24小时蛋白尿下降22.2%
- 治疗12个月eGFR保持稳定,与此前年下降5.63 ml/min per 1.73 m2形成对比
- 9例快速肾功能进展者中8例年eGFR斜率≤3 ml/min
核心结论
- 达格列净与法布雷病合并白蛋白尿性CKD患者白蛋白尿、蛋白尿及eGFR下降的减少相关,为期12个月。
研究设计与样本
- 入选条件为eGFR≥25 ml/min,且已接受稳定ERT或米加司他及最大耐受剂量RAS-i治疗。
- 在达格列净启动前12个月(T0)、启动时(T1)及12个月随访(T2)评估蛋白尿、UACR、eGFR和血压。
主要发现
- 12个月后UACR下降47.6%(300.1 [IQR: 106.5-856.1] mg/g vs. 142.5 [IQR: 60.7-415.7] mg/g;P = 0.01)。
- 24小时蛋白尿下降22.2%(0.45 [IQR: 0.31-1.67] g/d vs. 0.35 [IQR: 0.18-1.42] g/d;P < 0.001)。
- 校正年龄、性别、eGFR、法布雷病表型及ERT/米加司他治疗后,混合效应模型证实达格列净降低24小时蛋白尿(P < 0.001)。
- eGFR保持稳定(63.50 [SD: 25.13] vs. 64.31 [SD: 26.40] ml/min per 1.73 m2;P = 0.65),而T0至T1期间年下降为-5.63 [SE: 1.78] ml/min per 1.73 m2。
- 9例快速肾功能进展患者中8例在T1至T2期间年eGFR斜率≤3 ml/min。
临床怎么用
- 对接受ERT或米加司他及RAS-i治疗、合并白蛋白尿性CKD的法布雷病患者,可考虑加用达格列净以降低蛋白尿并稳定肾功能。
- 治疗期间应监测UACR、24小时蛋白尿及eGFR变化以评估疗效。
局限性
- 研究为前瞻性多中心设计但缺乏对照组,结论需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been demonstrated to reduce proteinuria and disease progression in people with chronic kidney disease (CKD), but data in Fabry disease (FD) are scant. This prospective, multicenter study evaluated the 12-month effects of dapagliflozin 10 mg/dL on albuminuria, proteinuria, and renal function in patients with FD and albuminuric CKD. METHODS: Adults with FD and albuminuric CKD (estimated glomerular filtration rate [eGFR] ≥ 25 ml/min) despite stable enzyme replacement therapy (ERT) or migalastat and maximally tolerated dose of renin-angiotensin system inhibitors (RAS-i) were included. Proteinuria, urinary albumin-to-creatinine ratio (UACR), eGFR, and blood pressure were assessed 12 months before dapagliflozin initiation (T0), at treatment initiation (T1), and at 12-month follow-up (T2). RESULTS: Sixteen patients were enrolled. After 12 months of dapagliflozin, UACR and 24-hour proteinuria decreased by 47.6% (300.1 [interquartile range, IQR: 106.5-856.1] mg/g [T1] vs. 142.5 [IQR: 60.7-415.7) mg/g [T2]; P = 0.01) and 22.2% (0.45 [IQR: 0.31-1.67] g/d [T1] vs. 0.35 [IQR: 0.18-1.42] g/d [T2]; P < 0.001), respectively. Mixed-effects model analysis confirmed the effect of dapagliflozin on reducing 24-hour proteinuria (P < 0.001), after adjustment for age, sex, eGFR, FD phenotype and ERT/migalastat treatments. eGFR remained stable (63.50 [SD: 25.13] ml/min per 1.73 m2 [T1] vs. 64.31 [SD: 26.40] ml/min per 1.73 m2 [T2]; P = 0.65), contrasting with annual decline (-5.63 [SE: 1.78] ml/min per 1.73 m2) during T0 to T1 period, adjusting for sex, age, FD phenotype, ERT/migalastat treatments and 24-hour proteinuria. Eight out of 9 fast renal progressor patients achieved an annual eGFR slope ≤ 3 ml/min during the T1 to T2 period. CONCLUSION: this preliminary evidence shows that dapagliflozin was associated with reduction in albuminuria, proteinuria, and eGFR decline in patients with FD and albuminuric CKD receiving ERT or migalastat and RAS-i over 12 months.
引用
- Battaglia Y, Vitturi N, Marchi G, et al. Dapagliflozin in Patients With CKD With Fabry Disease. Kidney Int Rep. 2025. PMID: 41704902. doi:10.1016/j.ekir.2025.103742
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。